102 related articles for article (PubMed ID: 3931293)
1. Pasteurization of antihemophilic factor and model virus inactivation studies.
Ng PK; Dobkin MB
Thromb Res; 1985 Aug; 39(4):439-47. PubMed ID: 3931293
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Mauler R; Merkle W; Hilfenhaus J
Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of viruses by pasteurization at 60 °C for 10 h with and without 40% glucose as stabilizer during a new manufacturing process of α2-Macroglobulin from Cohn Fraction IV.
Huangfu C; Ma Y; Jia J; Lv M; Zhu F; Ma X; Zhao X; Zhang J
Biologicals; 2017 Mar; 46():139-142. PubMed ID: 28215695
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization.
Hilfenhaus J; Herrmann A; Mauler R; Prince AM
Vox Sang; 1986; 50(4):208-11. PubMed ID: 3014743
[TBL] [Abstract][Full Text] [Related]
5. Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride.
Schlegel A; Immelmann A; Kempf C
Transfusion; 2001 Mar; 41(3):382-9. PubMed ID: 11274595
[TBL] [Abstract][Full Text] [Related]
6. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of viruses in labile blood derivatives. II. Physical methods.
Horowitz B; Wiebe ME; Lippin A; Vandersande J; Stryker MH
Transfusion; 1985; 25(6):523-7. PubMed ID: 3934802
[TBL] [Abstract][Full Text] [Related]
8. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
[TBL] [Abstract][Full Text] [Related]
9. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of parvovirus B19 during pasteurization of human serum albumin.
Blümel J; Schmidt I; Willkommen H; Löwer J
Transfusion; 2002 Aug; 42(8):1011-8. PubMed ID: 12385412
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus, hepatitis non-A, non-B virus and hepatitis delta virus in lyophilized antihemophilic factor: relative sensitivity to heat.
Purcell RH; Gerin JL; Popper H; London WT; Cicmanec J; Eichberg JW; Newman J; Hrinda ME
Hepatology; 1985; 5(6):1091-9. PubMed ID: 3934060
[TBL] [Abstract][Full Text] [Related]
12. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.
Savage M; Torres J; Franks L; Masecar B; Hotta J
Biologicals; 1998 Jun; 26(2):119-24. PubMed ID: 9811517
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of viruses and safety of stable plasma products.
Morgenthaler JJ
Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
[TBL] [Abstract][Full Text] [Related]
14. Effective inactivation of a wide range of viruses by pasteurization.
Gröner A; Broumis C; Fang R; Nowak T; Popp B; Schäfer W; Roth NJ
Transfusion; 2018 Jan; 58(1):41-51. PubMed ID: 29148053
[TBL] [Abstract][Full Text] [Related]
15. Liquid pasteurization of an immunoglobulin preparation without stabilizer: effects on its biological and biochemical properties.
Bridonneau P; Marcilly H; Vernois-Martin M; Goigoux P; Bourdel V; Laulan A; Deramoudt FX; Desmadril M; Sitbon M; Basuyaux B; Steinbuch M; Schmitthaeusler R
Vox Sang; 1996; 70(4):203-9. PubMed ID: 9123924
[TBL] [Abstract][Full Text] [Related]
16. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
17. Studies on the inactivation of human parvovirus 4.
Baylis SA; Tuke PW; Miyagawa E; Blümel J
Transfusion; 2013 Oct; 53(10 Pt 2):2585-92. PubMed ID: 24032592
[TBL] [Abstract][Full Text] [Related]
18. The Sterways process: a new approach to inactivating viruses using gamma radiation.
Reid BD
Biologicals; 1998 Jun; 26(2):125-9. PubMed ID: 9811518
[TBL] [Abstract][Full Text] [Related]
19. Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals.
Saknimit M; Inatsuki I; Sugiyama Y; Yagami K
Jikken Dobutsu; 1988 Jul; 37(3):341-5. PubMed ID: 3416941
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption.
Hiemstra H; Nieuweboer CE; Idoe MA; Claassen JE; Vos AH; Tersmette M; Strengers PF; Over J; Mauser-Bunschoten EP; Heijboer H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):557-63. PubMed ID: 1714860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
